ESMO: Pfizer's narrow Ibrance survival miss could still sway docs in its favor: exec
admin 20th October 2018 Uncategorised 0Pfizer’s Ibrance may have failed to show it could help some breast cancer patients live longer. But execs say digging into those study results—from the closely watched Paloma-3 trial—still reveals a “compelling” case.
More: ESMO: Pfizer's narrow Ibrance survival miss could still sway docs in its favor: exec
Source: fierce